Drug Profile
Research programme: pain therapeutics - Algynomics
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Algynomics
- Class Analgesics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pain
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Pain in USA
- 02 Aug 2016 Research programme: pain therapeutics - Algynomics is available for licensing as of 02 Aug 2016. http://www.algynomics.com/
- 02 Aug 2016 Early research in Pain in USA (unspecified route)